Cure8 research brief
This study provides real-world data on how well ustekinumab is kept on treatment and its safety in an Arab IBD population—information that can help patients and clinicians understand longer-term use outside clinical trials.
Adult patients with Crohn's disease or ulcerative colitis (especially those considering or on ustekinumab), IBD clinicians, and researchers studying biologic outcomes in MENA populations.
This study looked at 345 treatment episodes (216 CD, 129 UC) across two referral centers in Qatar. Drug retention at 6, 12, and 24 months was 92.2%, 83.9%, and 77.8%, respectively, with CD patients showing higher early retention than UC. Discontinuations were mainly for primary non-response or secondary loss of response.
Adverse events were uncommon and serious adverse events rare; no deaths or malignancies were reported. The findings are from a retrospective chart review in a predominantly Arab population and describe real-world use rather than a randomized trial. The authors note the need for prospective studies to confirm these patterns in MENA populations.
Results come from a retrospective cohort at two referral centers in Qatar and are summarized in the article abstract. Prospective studies would be needed to confirm predictors of discontinuation and generalize findings to other settings.
Review the original publication for the complete reporting, methods, and context.
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
New trial and real-world data about Skyrizi and Rinvoq could affect treatment options and conversations about long-term outcomes for people with Crohn’s disease or ulcerative colitis. Investors’ coverage can increase...
This review pools available pediatric data showing ustekinumab can induce and maintain remission after anti‑TNF failure, offering a treatment option for children with refractory IBD. Results are most robust for Crohn’s...
A new FDA approval means another biologic option for people with moderately to severely active Crohn’s disease, including patients who have failed or not tolerated prior therapies.
